Please ensure Javascript is enabled for purposes of website accessibility

Teva Donating More Than 10 Million Doses of Hydroxychloroquine as Potential COVID-19 Treatment

By Brian Orelli, PhD - Mar 20, 2020 at 3:43PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Preliminary studies done in China suggest the decades-old malaria drug could inhibit the growth of the novel coronavirus.

Teva Pharmaceutical (TEVA -0.44%) plans to donate 10 million tablets of the malaria drug hydroxychloroquine sulfate as a potential treatment for COVID-19. That news follows a report from earlier this week that Bayer (BAYR.Y 0.71%) plans to donate 3 million tablets of the related drug chloroquine, which is more potent but has more hazardous side effects.

Teva has 6 million tablets on hand, which it plans to ship through wholesalers to hospitals by March 31, with the remaining doses expected to be ready within a month.

Hydroxychloroquine and chloroquine are best-known as treatments for malaria, which is caused by a parasite, not a virus. Hydroxychloroquine is also prescribed for autoimmune diseases. But recent studies reported on in the journal Nature have found both drugs inhibit the ability of the SARS-CoV-2 coronavirus to replicate in the laboratory. How well the drug might  do to help humans fight off the disease is still unknown, although initial reports have been positive.

On Thursday, Mylan (MYL) said it restarted production of its hydroxychloroquine sulfate tablets with plans to ramp up production to 50 million tablets, which could treat more than 1.5 million people. Mylan didn't mention anything about donating its product, but both chloroquine and hydroxychloroquine have been around for decades and are off-patent. Even if Mylan charges for its generic drug, the treatment is likely to be cheap. This won't move Mylan's financials much considering it registered $11.5 billion in revenue last year, and will only get bigger after its merger with Pfizer's (PFE -0.15%) Upjohn division.

While they're not going to make much profit with these moves, Bayer, Teva, and Mylan should certainly earn some goodwill and positive PR.

Caution Outbreak Alert sign on a door with a patient and doctor in background

Image source: Getty Images.

At a White House Briefing on Friday, when asked about whether chloroquine had been approved by the Food and Drug Administration as a treatment for COVID-19, Anthony Fauci, the head of the National Institute of Allergy and Infectious Diseases replied, "The answer is no, and the evidence that you're talking about...is anecdotal evidence," according to Business Insider.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$9.04 (-0.44%) $0.04
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$53.91 (-0.15%) $0.08
Viatris Inc. Stock Quote
Viatris Inc.
MYL
Bayer Stock Quote
Bayer
BAYR.Y
$17.77 (0.71%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
344%
 
S&P 500 Returns
120%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.